Whether diagnosing suspicious symptoms or determining treatment next steps, deciding on the best path forward can be a challenging and uncertain endeavor without the right data. Our diagnostic and prognostic tests provide clarity for some of the most complex diseases, helping patients avoid unnecessary procedures and speeding time to appropriate diagnosis and treatment.
Understanding cancer at the molecular level enables more personalized approaches to diagnosis and treatment. We collaborate closely with clinicians and scientists to identify unmet needs that stand in the way of better care. And then, we find the answers. Our rigorous process enables more confident decision-making for clinicians, giving patients access to a higher standard of care. The number of people globally each year who are diagnosed with a cancer that our tests address.
We work with clinicians and scientists to develop our tests. We take a rigorous approach to ensuring product performance and utility, building evidence across a broad range of studies.
Clinicians and patients need high-quality, reliable results they can trust. We supplement this with our proven ability to build clinical evidence that drives reimbursement, encourages clinician adoption, and prompts guideline inclusion for our tests. Through our centralized CLIA lab-based approach in the US and our growing menu of distributed IVDs to serve global markets, we aim to transform cancer care for patients all over the world. Veracyte offers fulfilling career opportunities for curious, driven, and patient-oriented people who are inspired to find answers to some of the most challenging questions in medicine.
Join us. World Health Organization. Published February 3, Accessed July 19, Thyroid Cancer — Statistics. Bladder Cancer. International Agency for Research on Cancer. Who we are. Latest News. Read More.
